Download OncoMed Announces Abstracts Accepted at the 2014 ASCO Annual

April 23, 2014
OncoMed Announces Abstracts Accepted at the 2014 ASCO Annual Meeting
REDWOOD CITY, Calif., April 23, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinicalstage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced
that several abstracts have been accepted for presentation at the upcoming American Society for Clinical Oncology (ASCO)
Annual Meeting being held May 30 - June 3, 2014 in Chicago, IL.
OncoMed will present new clinical data from its ongoing studies, including the Phase 1b study of demcizumab (OMP-21M18,
anti-DLL4) in non-small cell lung cancer (NSCLC), the Phase 1/2 PINNACLE trial of OMP-59R5 (anti-Notch 2/3) in small-cell
lung cancer (SCLC) and the Phase 1 trial of OMP-54F28 (FZD8-Fc) in patients with advanced solid tumors. The list of
abstracts and timing of the presentations is provided below.
Oral Presentation
●
A first-in-human Phase 1 study of anti-cancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands,
in patients with advanced solid tumors. (Abstract# 2505)
Presenting author: Antonio Jimeno M.D., Ph.D., University of Colorado Cancer Center
Date and time: Saturday, May 31, 2014 at 1:15 PM - 4:15 PM CDT
Session: Oral Abstract Session - Developmental Therapeutics - Clinical Pharmacology and Experimental
Therapeutics
Posters
●
Phase 1b of anti-cancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with etoposide and cisplatin (EP) in
patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). (Abstract# 7601)
Presenting author: David R. Spigel, M.D., Sarah Cannon Research Institute
Date and time: Saturday, May 31, 2014 at 1:15 PM - 5:00 PM CDT
Session: General Poster Session - Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic
Cancers
●
A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in
pts with first-line nonsquamous NSCLC. (Abstract # 2544)
Presenting author: Mark McKeage, MBChB, MMedSc, Ph.D., FRACP, University of Auckland
Date and time: Sunday, June 1, 2014 at 8:00 am - 11:45 am CDT
Session: General Poster Session - Developmental Therapeutics - Clinical Pharmacology and Experimental
Therapeutics
About Cancer Stem Cells
Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the
tumor. Also known as tumor-initiating cells, CSCs have the capacity to divide and give rise to new cancer stem cells via a
process called self-renewal and to differentiate or change into the other cells that form the bulk of the tumor. Common cancer
drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor.
OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a nontumorigenic state, and also impact bulk tumor cells. OncoMed believes its product candidates are distinct from the current
generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the
clinical outcome of patients with cancer.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting
cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab
(anti-DLL4, OMP-21M18), OMP-59R5 (anti-Notch2/3), OMP-52M51 (anti-Notch1), vantictumab (anti-Fzd7, OMP-18R5), and
OMP-54F28 (Fzd8-Fc), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other
antibodies in preclinical development, OMP-305B83 (Anti-DLL4/Anti-VEGF bispecific) and Anti-RSPO3, with Investigational New
Drug filings planned for late 2014 or early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC product
candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).
Additional information can be found at the company's website: www.oncomed.com.
CONTACT: Investor Contact:
OncoMed Pharmaceuticals
Shari Annes
Investor Relations
(650) 888-0902
[email protected]
Media Inquiries:
BCC Partners
Karen L. Bergman or
Michelle Corral
(650) 575-1509 or (415) 794-8662
[email protected] or
[email protected]